Johnson & Johnson to buy Ollin Biosciences for $2.2bn
- Johnson & Johnson will pay $2.2bn upfront, with up to approximately $1.125bn in regulatory and commercial milestone payments.
- The acquisition is expected to close before the end of 2026, subject to regulatory approvals and customary conditions.
- Blackstone will provide $750m over multiple years to fund OLN324’s Phase 3 development, in exchange for milestone payments and single-digit royalties.
- OLN324 targets VEGF and Ang2 and is being developed for wet age-related macular degeneration and diabetic macular edema.
Acquisition terms
Johnson & Johnson has agreed to acquire clinical-stage biopharmaceutical company Ollin Biosciences for $2.2bn upfront, with potential regulatory and commercial milestone payments of approximately $1.125bn. The transaction is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions.
Separately, Blackstone Life Sciences will pay Johnson & Johnson $750m over multiple years to fund Phase 3 development of OLN324. Blackstone will be eligible for regulatory and sales milestone payments and single-digit royalties.
OLN324
The acquisition would add OLN324, an investigational bispecific antibody, to Johnson & Johnson’s pipeline. The candidate targets vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2) and is being developed for wet age-related macular degeneration and diabetic macular edema. The company describes it as a small-format antibody with high Ang2 potency, designed to improve control of retinal fluid.
Source: J&J